Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Medico Remedies Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Day's Range
Low
₹44.41
High
₹46.26
Price Summary
| Previous Close | ₹45.35 |
|---|---|
| Day's Range | ₹44.41 - ₹46.26 |
| Open | ₹46.26 |
| 52 Week Range | ₹30.22 - ₹56.88 |
| Volume | 2,57,932 |
| Market Cap | ₹0.00 |
| Previous Close | ₹45.31 |
|---|---|
| Day's Range | ₹44.77 - ₹50.10 |
| Open | ₹50.10 |
| 52 Week Range | ₹31.00 - ₹56.99 |
| Volume | 2,852 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 116.97 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 29.13 |
| TTM EPS (₹) | 1.58 |
| P/E Ratio | 42.83 |
| Book Value(₹) | 5.06 |
| PAT Margin (%) | 6.69 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.65 |
| Trade Value ( ₹ in Lacs) | 1.29 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 29.13 |
| TTM EPS (₹) | 1.58 |
| P/E Ratio | 42.83 |
| Book Value(₹) | 5.06 |
| PAT Margin (%) | 6.69 |
| Face Value (₹) | 2.00 |
| ROCE(%) | 21.65 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 1509.41 | 413.03 |
| Expenses | N/A | N/A |
| PBT | 135.04 | 56.98 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 100.93 | 43.41 |
About Medico Remedies Ltd.
| Founded | 1994 |
|---|---|
| Managing Director | Harshit Mehta |
| NSE Symbol | MEDICO |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,77,407.68 | 2,014.45 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,06,906.21 | 7,917.90 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,85,520.62 | 4,879.75 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,28,423.42 | 8,999.00 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,19,031.97 | 1,471.60 | 1,165.70 - 1,165.70 |
| Lupin Ltd. | 1,12,013.40 | 2,431.80 | 1,836.80 - 1,836.80 |
| Zydus Lifesciences Ltd. | 1,11,959.83 | 1,121.85 | 835.50 - 835.50 |
| Max Healthcare Institute Ltd. | 1,08,155.01 | 1,128.00 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,07,071.27 | 2,574.30 | 1,909.70 - 1,909.70 |
| Lenskart Solutions Ltd. | 97,264.03 | 563.20 | 0.00 - 0.00 |
No Records Found
Latest News
Jul
30
2026
Posted on Jul 30th 2026
Aurobindo Pharma informs about press release
Aurobindo Pharma has informed that it enclosed copies of the Notice published in the newspapers, Business Standard and Nava Telangana on July 30, 2026, intimating the shareholders that the 39th Annual General Meeting of the Company will be held on Thursday, August 27, 2026, at 3:30 pm (IST) through Video Conferencing / Other Audio-Visual Means.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Goldline Pharmaceutical informs about disclosure
Goldline Pharmaceutical has informed that the exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Prashant Shrikrishna Karkare.
The above information is a part of company’s filings submitted to BSE.
Read More
Jul
30
2026
Posted on Jul 30th 2026
Jagsonpal Pharma - Quaterly Results
The revenue for the June 2026 quarter is pegged at Rs. 822.32 millions, about 8.76% up against Rs. 756.12 millions recorded during the year-ago period.A humble growth in net profit of 22.18% reported in the quarter ended June 2026 to Rs. 131.89 millions from Rs. 107.95 millions.The company reported a good operating profit of 200.73 millions compared to 170.38 millions of corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 822.32 | 756.12 | 8.76 | 822.32 | 756.12 | 8.76 | 2872.25 | 2687.16 | 6.89 |
| Other Income | 28.33 | 28.25 | 0.28 | 28.33 | 28.25 | 0.28 | 119.95 | 81.90 | 46.46 |
| PBIDT | 200.73 | 170.38 | 17.81 | 200.73 | 170.38 | 17.81 | 700.69 | 592.61 | 18.24 |
| Interest | 2.51 | 2.54 | -1.18 | 2.51 | 2.54 | -1.18 | 10.28 | 9.58 | 7.31 |
| PBDT | 198.22 | 167.84 | 18.10 | 198.22 | 167.84 | 18.10 | 669.62 | 779.90 | -14.14 |
| Depreciation | 21.42 | 23.53 | -8.97 | 21.42 | 23.53 | -8.97 | 94.44 | 81.31 | 16.15 |
| PBT | 176.80 | 144.31 | 22.51 | 176.80 | 144.31 | 22.51 | 575.18 | 698.59 | -17.67 |
| TAX | 44.91 | 36.36 | 23.51 | 44.91 | 36.36 | 23.51 | 144.36 | 144.98 | -0.43 |
| Deferred Tax | 3.13 | 4.65 | -32.69 | 3.13 | 4.65 | -32.69 | 12.49 | 9.26 | 34.88 |
| PAT | 131.89 | 107.95 | 22.18 | 131.89 | 107.95 | 22.18 | 430.82 | 553.61 | -22.18 |
| Equity | 131.68 | 133.06 | -1.04 | 131.68 | 133.06 | -1.04 | 133.93 | 132.80 | 0.85 |
| PBIDTM(%) | 24.41 | 22.53 | 8.33 | 24.41 | 22.53 | 8.33 | 24.40 | 22.05 | 10.62 |
Read More
Jul
30
2026
Posted on Jul 30th 2026
Eris Lifesciences - Quaterly Results
The sales for the June 2026 quarter moved down to Rs. 4439.90 millions as compared to Rs. 5786.40 millions during the year-ago period.A big decline of -51.70% was reported for the quarter ended June 2026 to Rs. 483.00 millions from Rs. 999.90 millions of corresponding previous quarter.The company reported a degrowth in operating Profit to 1462.80 millions from 2390.00 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202606 | 202506 | % Var | 202606 | 202506 | % Var | 202603 | 202503 | % Var | |
| Sales | 4439.90 | 5786.40 | -23.27 | 4439.90 | 5786.40 | -23.27 | 18217.40 | 16977.50 | 7.30 |
| Other Income | 263.80 | 226.80 | 16.31 | 263.80 | 226.80 | 16.31 | 983.10 | 355.10 | 176.85 |
| PBIDT | 1462.80 | 2390.00 | -38.79 | 1462.80 | 2390.00 | -38.79 | 7106.40 | 5220.60 | 36.12 |
| Interest | 421.60 | 451.40 | -6.60 | 421.60 | 451.40 | -6.60 | 1795.40 | 2202.40 | -18.48 |
| PBDT | 1041.20 | 1938.60 | -46.29 | 1041.20 | 1938.60 | -46.29 | 5164.30 | 3018.20 | 71.11 |
| Depreciation | 399.80 | 376.00 | 6.33 | 399.80 | 376.00 | 6.33 | 1543.80 | 1817.70 | -15.07 |
| PBT | 641.40 | 1562.60 | -58.95 | 641.40 | 1562.60 | -58.95 | 3620.50 | 1200.50 | 201.58 |
| TAX | 158.40 | 562.70 | -71.85 | 158.40 | 562.70 | -71.85 | 1180.00 | 426.60 | 176.61 |
| Deferred Tax | 56.10 | 291.00 | -80.72 | 56.10 | 291.00 | -80.72 | 570.40 | 206.80 | 175.82 |
| PAT | 483.00 | 999.90 | -51.70 | 483.00 | 999.90 | -51.70 | 2440.50 | 773.90 | 215.35 |
| Equity | 138.60 | 136.20 | 1.76 | 138.60 | 136.20 | 1.76 | 138.50 | 136.20 | 1.69 |
| PBIDTM(%) | 32.95 | 41.30 | -20.23 | 32.95 | 41.30 | -20.23 | 39.01 | 30.75 | 26.86 |
Read More
Jul
29
2026
Posted on Jul 29th 2026
Indoco Remedies informs about press release
Indoco Remedies has informed that it enclosed copies of the newspaper advertisement published today 29th July, 2026 in Business Standard (All India Editions) (English Newspaper) and Mumbai Lakshadeep (Marathi Newspaper) with respect to the extract of Unaudited Standalone and Consolidated Financial Results of the Company for the Quarter Ended 30th June, 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Medico Remedies Ltd. is ₹45.35 as of 2026-07-30.
The market capitalisation of Medico Remedies Ltd. is ₹382.06 as of 2026-07-29.
The 1-year return of Medico Remedies Ltd. is 5.01% as of 2026-07-30.
The P/E ratio of Medico Remedies Ltd. is 42.83 as of 2026-07-30.
The 52-week high and low of Medico Remedies Ltd. are ₹56.88 and ₹30.22, respectively, as of 2026-07-30.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
